Well cool. When you look for answers on the science/statistical analysis to base your investments on, this immunologist/infectious disease provider will not likely want to “hold hands” with several here. Good luck with your thrashings in the dark. The first shareholder’s meeting should include mandatory pseudonym nametags. That would be a hoot. PM me if you desire any explanations as the science and trials unfold. Will decide if you warrant a reply